There are currently 538 clinical trials in Madison, Wisconsin looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Wisconsin, University of Wisconsin Hospital and Clinics, University of Wisconsin-Madison and University of Wisconsin Carbone Cancer Center - University Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
NCT05180773
Recruiting
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/19/2025
Locations: University of Wisconsin Madison, Madison, Wisconsin
Conditions: Peripartum Cardiomyopathy, Postpartum
Register for Updates
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654
Recruiting
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Triple Negative Breast Cancer
Register for Updates
Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer
NCT06228053
Recruiting
The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed abiraterone.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
Combined Electric and Acoustic Hearing (EAS) in Children and Adults
NCT05923203
Recruiting
Cochlear implants are surgically implanted devices which restore the ability to hear to the hearing impaired. Improvements in surgery and electrodes have results in an increased number of adults and children who have residual hearing and can benefit from electric and acoustic hearing in the same ear. This is called Electric Acoustic Stimulation (EAS). Many studies have shown that adult EAS users show significant benefits for speech understanding in noise and spatial hearing tasks as compared to... Read More
Gender:
ALL
Ages:
5 years and above
Trial Updated:
04/18/2025
Locations: University Of Wisconsin Madison, Madison, Wisconsin
Conditions: Cochlear Implant, Hearing Loss
Register for Updates
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
NCT05585320
Recruiting
This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 candidate optimal dose of IMM-1-104 to further explore the anti-tumor activity of I... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: University of Wisconsin Clinical Science Center, Madison, Wisconsin
Conditions: Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC), Advanced Solid Tumor
Register for Updates
Biomarkers to Detect Endocrine Therapy Resistance
NCT06067503
Recruiting
This pilot observational study is being done to identify possible biomarkers of response to endocrine therapy in patients with ER/PR+ metastatic lobular breast cancer (LBC) starting new endocrine therapy. 18F-fluorofuranylnorprogesterone Positron Emission Tomography/Computed Tomography (FFNP-PET/CT) and liquid biopsies will be performed at baseline and after 4 weeks of treatment. Baseline levels and dynamic on-treatment changes in estrogen signaling as measured by FFNP-PET/CT and circulating tum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: UW Carbone Cancer Center, Madison, Wisconsin
Conditions: Metastatic Cancer, Breast Cancer, Lobular Breast Carcinoma
Register for Updates
Trauma-Informed Guilt Reduction Therapy Compared to Prolonged Exposure
NCT06296589
Recruiting
The goal of this clinical trial is to learn if receiving Trauma-Informed Guilt Reduction (TrIGR) Therapy is as effective as receiving Prolonged Exposure Therapy among veterans with PTSD and trauma related guilt. The main questions it aims to answer are: Will TrIGR be comparable to PE in terms of PTSD symptom reduction? Will it TrIGR be comparable to PE in improving functioning and reducing depression symptoms? Will it be superior in improving trauma-related guilt and shame?
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: William S. Middleton Memorial Hospital, Madison, Wisconsin
Conditions: Stress Disorders, Post-Traumatic
Register for Updates
UWCCC Molecular Tumor Board Registry
NCT03023202
Recruiting
This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Hematologic Neoplasms, Solid Neoplasm
Register for Updates
AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion
NCT06029660
Recruiting
To determine the safety and effectiveness of IMPEDE-FX RapidFill to increase the percentage of subjects with shrinkage of the abdominal aortic aneurysm sac when used as an adjunct to on-label endovascular aneurysm repair (EVAR) stent graft treatment in trial subjects considered candidates for elective EVAR.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Aortic Aneurysm, Abdominal
Register for Updates
Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration
NCT06381596
Recruiting
The goal of this clinical trial is to learn if the areas of stressed cells in the retina correlate to areas of disease identified in standard imaging and whether the images are helpful to identify potential areas of concern before symptoms or disease occurs. The main question it aims to answer is: * to evaluate patterns of increased autofluorescence FPF in the setting of geographic atrophy Participants will undergo FPF imaging using the OcuMet Beacon system.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/16/2025
Locations: Department of Ophthalmology and Visual Sciences, Madison, Wisconsin
Conditions: Geographic Atrophy, Age-Related Macular Degeneration
Register for Updates
Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
NCT06199713
Recruiting
The purpose of this research study is to determine if analysis of PET/CT scans and testing of blood samples in people with melanoma that has spread in their body can help researchers determine which patients are more or less likely to respond to immunotherapy and are more or less likely to have side effects. 24 participants will be enrolled and be on study until approximately 4 weeks after their first dose of Immune Checkpoint Inhibitor therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: University of Wisconsin Hospitals and Clinics (UWHC), Madison, Wisconsin
Conditions: Melanoma, Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
Register for Updates
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
NCT06305624
Recruiting
This protocol describes a randomized controlled trial testing the effectiveness and implementability of the CHESS Health Connections smartphone application among patients with alcohol-associated liver disease (ALD) at two medical centers in Michigan and Wisconsin, in two types of clinics: general hepatology and multidisciplinary that offers care for advanced ALD alongside co-located, integrated mental health and substance abuse treatment. The long-term goal of this and future work is to prevent... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: UW General Hepatology Clinic, Madison, Wisconsin +1 locations
Conditions: Alcohol Use Disorder, Alcohol-related Liver Disease
Register for Updates